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o avoid immune recognition by cytotoxic T lympho-
cytes (CTLs), human immunodeﬁciency virus (HIV)-1
Nef disrupts the transport of major histocompatibil-
ity complex class I molecules (MHC-I) to the cell surface in
HIV-infected T cells. However, the mechanism by which
Nef does this is unknown. We report that Nef disrupts
MHC-I trafﬁcking by rerouting newly synthesized MHC-I
from the trans-Golgi network (TGN) to lysosomal com-
partments for degradation. The ability of Nef to target
MHC-I from the TGN to lysosomes is dependent on ex-
T
 
pression of the 
 
 
 
1 subunit of adaptor protein (AP) AP-1A,
a cellular protein complex implicated in TGN to endoly-
sosomal pathways. We demonstrate that in HIV-infected
primary T cells, Nef promotes a physical interaction
between endogenous AP-1 and MHC-I. Moreover, we
present data that this interaction uses a novel AP-1 binding
site that requires amino acids in the MHC-I cytoplasmic
tail. In sum, our evidence suggests that binding of AP-1 to
the Nef–MHC-I complex is an important step required for
inhibition of antigen presentation by HIV.
 
Introduction
 
The human immunodeficiency virus (HIV) establishes a chronic
infection in T lymphocytes by evading the host immune re-
sponse. To prevent recognition and killing by host cytotoxic T
lymphocytes (CTLs), HIV reduces the cell surface expression
of major histocompatibility complex class I molecules (MHC-I)
(Schwartz et al., 1996), which are needed to present antigenic
peptides to CTLs. The HIV Nef protein is required for the
reduced MHC-I cell surface expression (Schwartz et al., 1996)
and to thereby protect HIV-infected primary T cells from anti-
HIV CTLs (Collins et al., 1998).
HIV-1 Nef is a 27–34-kD multifunctional protein that has
no apparent enzymatic activity and is thought to function by act-
ing as an adaptor protein (AP). Consistent with this, Nef binds
to cytoplasmic tail domains (Harris and Neil, 1994; Greenway et
al., 1995; Grzesiek et al., 1996; Rossi et al., 1996; Schaefer et
al., 2000; Williams et al., 2002), and contains a number of po-
tential protein–protein interaction domains that are required
either for MHC-I or CD4 downmodulation. An NH
 
2
 
-terminal 
 
 
 
helical domain, an acidic domain and a polyproline repeat are all
required for MHC-I downmodulation (Greenberg et al., 1998b;
Mangasarian et al., 1999). In contrast, dileucine and diacidic
motifs within Nef are necessary for removal of cell surface CD4
(Aiken et al., 1994; Greenberg et al., 1998b).
Thus far, Nef has been shown to downmodulate all
MHC-I HLA-A and HLA-B allotypes. However, Nef does not
downmodulate MHC-I HLA-C and HLA-E (Le Gall et al.,
1998; Cohen et al., 1999). This selective downmodulation re-
sults from amino acid sequence variation in the Nef binding
domain within the cytoplasmic tails of these molecules (Wil-
liams et al., 2002). Because HLA-C and HLA-E are known to
inhibit natural killer cell lysis, it has been proposed that mainte-
nance of their cell surface expression may allow survival of the
infected cell (Le Gall et al., 1998; Cohen et al., 1999).
The current model for how Nef affects CD4 cell surface
expression is that Nef binds to the CD4 cytoplasmic tail and links
it to cellular trafficking proteins that accelerate its endocytosis.
Indeed, Nef is known to interact with a number of proteins that
regulate intracellular trafficking. For example, Nef interacts
with the heterotetrameric clathrin APs (AP-1, AP-2, and/or
AP-3; Bresnahan et al., 1998; Greenberg et al., 1998a; Le Gall
et al., 1998; Piguet et al., 1998; Craig et al., 2000; Erdtmann et
al., 2000; Janvier et al., 2003a,b), through the same dileucine
motif that is needed for CD4 downmodulation (Bresnahan et
al., 1998; Greenberg et al., 1998a; Craig et al., 2000; Janvier et
al., 2003a,b).
The adaptin complexes (Robinson and Bonifacino, 2001;
Traub, 2003; Robinson, 2004) are each composed of four sub-
units; two large subunits (
 
 
 
1, 
 
 
 
2, 
 
 
 
3 plus 
 
 
 
, 
 
 
 
, or 
 
 
 
), medium
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subunit (
 
 
 
1A, 
 
 
 
1B, 
 
 
 
2, 
 
 
 
3) and one small subunit (
 
 
 
1, 
 
 
 
2,
 
 
 
3) for AP-1 (A or B), AP-2 and AP-3, respectively. There is
evidence that all of these complexes sort proteins by binding
recognition sequences in their cytoplasmic tails and linking
them to clathrin. AP-1 is localized to the TGN and endosomes.
Thus, it is thought to be important for trafficking between these
compartments (Doray et al., 2002; Waguri et al., 2003), and for
eventual sorting of some proteins (e.g., lysosomal hydrolases)
to the lysosomes. AP-3 is localized to endosomes (Peden et al.,
2004) and is needed for proper targeting of other proteins (e.g.,
lysosome-associated membrane protein [LAMP-1]) to lyso-
somes. Finally, AP-2 is localized to the cell surface and plays a
role in endocytosis (Traub, 2003). Thus, one model is that Nef-
dependent CD4 endocytosis occurs via recruitment of AP-2
through Nef’s dileucine motif. Nef-dependent CD4 endocyto-
sis may additionally require interaction with a subunit of the
vacuolar ATPase (Lu et al., 1998), which may indirectly pro-
mote an association of Nef with AP-2 (Geyer et al., 2002).
However, the mechanistic details of how interactions of Nef
with various adaptin molecules accelerate CD4 endocytosis
and degradation are not well understood.
There is increasing evidence that Nef disrupts MHC-I
cell surface expression by a different mechanism than it uses to
downmodulate CD4. The diacidic motif needed for Nef to in-
teract with the vacuolar ATPase to promote CD4 down-regula-
tion is not required for Nef to disrupt MHC-I trafficking
(Greenberg et al., 1998b; Lu et al., 1998). In addition, the dileu-
cine motif within Nef that is required for Nef to directly bind
adaptin complexes is also dispensable (Greenberg et al., 1998b;
Mangasarian et al., 1999). Moreover, in HIV-infected T lym-
phocytes and astrocytic cells, the primary effect of Nef on
MHC-I is to disrupt its transport to the cell surface rather than
to promote its endocytosis (Swann et al., 2001; Kasper and
Collins, 2003). The molecular mechanism underlying this ef-
fect of Nef is unknown.
To determine how Nef disrupts the transport of MHC-I to
the cell surface, we used biochemical and cell biological ap-
proaches to examine MHC-I trafficking in Nef-expressing T
cells. We found that Nef redirected MHC-I from the TGN to
lysosomes. Moreover, we demonstrated that the AP, AP-1,
which is required for proper sorting of lysosomal hydrolases
from the TGN to lysosomes, was required for Nef to disrupt
MHC-I trafficking. Finally, in HIV-infected primary T cells,
we found that Nef stabilized an interaction between MHC-I
and AP-1. This interaction used a novel domain that required
sequences from the NH
 
2
 
-terminal 
 
 
 
 helix of Nef and from the
MHC-I cytoplasmic tail.
 
Results
 
To perform large scale biochemical experiments to examine
the effects of Nef on MHC-I trafficking in T cells, we devel-
oped a system that permitted transient, uniform, expression of
Nef in T cells. This was accomplished by using a replication-
defective adenoviral vector expressing HIV-1 Nef, which dis-
rupts MHC-I transport in a manner that is indistinguishable
from HIV (Kasper and Collins, 2003). In addition, to specifi-
cally detect an allotype of MHC-I that is responsive to Nef, we
attached an HA tag to the NH
 
2
 
-terminal extracellular domain of
HLA-A2. Based on a number of biochemical measurements,
the tagged molecule was folded properly, matured through the
secretory pathway normally, and was equally responsive to
HIV-1 Nef (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200407031/DC1).
 
Trafficking of MHC-I in Nef-expressing 
T cells
 
It has been previously shown that Nef does not affect the
transport of MHC-I into the medial Golgi apparatus (Schwartz
et al., 1996), but does inhibit its transport to the cell surface
(Kasper and Collins, 2003). To further define where in the
secretory pathway Nef exerts its effects, we asked whether
MHC-I was transported normally into the TGN. This was ac-
complished by monitoring the rate at which HLA-A2 ac-
quired sialic acid residues in this compartment, which can be
measured by testing sensitivity to neuraminidase digestion.
We detected sialylation of HLA-A2 as a slight increase in
HLA-A2 molecular weight (Fig. 1 A, lanes 4 and 7) that was
eliminated by neuraminidase treatment (Fig. 1 A, lanes 5 and
8). Based on these data (quantified in Fig. 1 B), Nef does not
delay the transport of HLA-A2 into the TGN. As a control,
we also confirmed the previously published observation that
Nef does not affect transit into the medial Golgi (Schwartz et
al., 1996), as assessed by sensitivity to endoglycosidase H
(endo H) digestion (Fig. 1, A and B).
 
HIV-1 Nef causes HLA-A2 to be 
degraded in lysosomal compartments
 
There is consensus that Nef causes the accumulation of MHC-I
in the TGN of multiple non-T cell lines (Schwartz et al., 1996;
Greenberg et al., 1998b; Le Gall et al., 1998; Piguet et al.,
2000; Swann et al., 2001; Blagoveshchenskaya et al., 2002).
However, it is controversial as to whether MHC-I is ultimately
targeted to other organelles in which it is degraded at an accel-
erated rate (Schwartz et al., 1996; Blagoveshchenskaya et al.,
2002; Williams et al., 2002). In agreement with other studies
performed in T cells (Schwartz et al., 1996), we found that Nef
expression accelerated the degradation of mature, endo H re-
sistant HLA-A2, but did not affect the stability of immature,
endo H–sensitive molecules (Fig. S2, available at http://www.
jcb.org/cgi/content/full/jcb.200407031/DC1). In addition, we
found that two inhibitors of lysosomal protein degradation,
ammonium chloride and bafilomycin A1, blocked HLA-A2
degradation. Whereas, lactacystin, a proteasome inhibitor, had
no effect on HLA-A2 degradation (Fig. 1 C). Thus, after reach-
ing the TGN, HLA-A2 appears to be targeted for lysosomal
degradation in Nef-expressing T cells.
To provide supporting evidence that MHC-I is ultimately
targeted to lysosomes, we examined the colocalization of
HLA-A2 with LAMP-1, a marker of lysosomal compartments
(Fig. 1 D). In T cells expressing Nef, we observed a very small
amount of colocalization of HLA-A2 with LAMP-1 (Fig. 1 D,
10). The majority colocalized with markers of the TGN (not
depicted). However, when lysosomal degradation was inhib- 
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ited by treatment of cells with bafilomycin A1, the amount of
HLA-A2 colocalizing with LAMP-1 dramatically increased in
Nef-expressing cells (Fig. 1 D, compare 10 with 12). These
data support the model that MHC-I is ultimately directed to ly-
sosomal compartments in Nef-expressing T cells, where it is
rapidly degraded.
 
Nef targets HLA-A2 to lysosomes using 
an AP-1A–dependent pathway
 
Transport of lysosomal hydrolases and LAMP-1 to the lyso-
somes is known to require the APs AP-1 and AP-3, respec-
tively. Interestingly, both of these adaptors are known to
interact with HIV-1 Nef. Therefore, to explore a possible
requirement for these complexes, we transfected cells with
siRNAs directed at the 
 
 
 
 subunit of AP-1A and AP-3. As
shown in Fig. 2 (A and B), we were able to reduce expression
of these molecules in both astrocytic cells and T cells. The ef-
fect was more dramatic in astrocytic cells, probably because
we were able to transfect them more efficiently than T cells.
In both cell types, we found that inhibiting the expression of
AP-1A, but not that of AP-3, reduced the effect of Nef on
MHC-I cell surface expression (Fig. 2, C and D). In addition,
Figure 1. HIV-1 Nef redirects MHC-I from the TGN
to lysosomes. (A and B) Nef does not affect the matu-
ration of HLA-A2 through the TGN. CEM HA-HLA-A2
cells were transduced with a control adenovirus (nef
 )
or an adenovirus expressing HIV-1 Nef (nef
 ) and
subjected to a pulse-chase metabolic labeling assay
to follow proteins through the biosynthetic pathway.
HA-HLA-A2 species with different gel mobilities were
identified based on enzymatic digestion profiles: (a)
N-glycosylated and sialylated HA-HLA-A2; (b) N-glyco-
sylated HA-HLA-A2; and (c) core HA-HLA-A2 protein.
(B) Quantitation of the relative percentage of endo H
resistant and sialylated HA-HLA-A2. The mean per-
centage   SD from two independent experiments is
plotted over time. (C) Nef-induced degradation of
mature MHC-I is blocked by inhibitors of acidic deg-
radation. CEM HA-HLA-A2 cells were treated with
adenovirus, pulsed with radioactive amino acids, and
were either collected immediately (lanes 1 and 2) or
chased for 4 h in media containing the indicated
chemical inhibitor (lanes 3–12). Cellular lysates were
divided equally, and HA-HLA-A2 or transferrin recep-
tor was recovered by immunoprecipitation. All samples
were digested with endo H before SDS-PAGE. The
results are representative of three independent experi-
ments.  (D) Bafilomycin A1 treatment increases the
degree of colocalization between HLA-A2 and LAMP-1.
Cells transduced with the indicated adenovirus were
treated with either solvent alone (DMSO) or bafilomycin
A1 (Baf A1) for 4 h before staining. HLA-A2 and
LAMP-1 were detected by indirect immunofluores-
cence using mAbs as described in Materials and
methods. Arrows indicate colocalization between
HLA-A2 and LAMP-1. Images were collected using a
confocal microscope. Individual z-sections are shown.
Bar, 5  m. 
JCB • VOLUME 167 • NUMBER 5 • 2004 906
 
AP-1A expression was required for HLA-A2 degradation
(Fig. 2 E). However, reducing the expression of 
 
 
 
1A and 
 
 
 
3
did not affect Nef’s ability to downmodulate CD4 (Fig. 2, C
and D), nor did it affect Nef expression (Fig. 2, A, B, and E).
These results suggest that AP-1A expression is specifically
required for Nef to disrupt MHC-I cell surface expression and
to target it for degradation.
 
Nef promotes the formation of a complex 
containing MHC-I and AP-1
 
To determine whether Nef functions as an AP linking
MHC-I to AP-1, we immunoprecipitated endogenous
HLA-A2 from HIV-infected primary T cells and then im-
munoblotted for Nef and for endogenous subunits of
AP-1. As expected, we detected Nef protein coprecipitat-
ing with HLA-A2 (Fig. 3 A). In addition, we also detected
the 
 
 
 
 and 
 
 
 
 subunits of AP-1 coprecipitating with HLA-
A2. This result is particularly striking because only 
 
 
 
25%
of the primary T cells were infected in this experiment.
The interaction was highly specific based on the fact that
the related AP, AP-3, did not coprecipitate with HLA-A2
(Fig. 3 B). Thus, these studies strongly indicate that Nef
promotes the formation of a complex containing MHC-I
and AP-1.
Figure 2. HIV-1 Nef targets MHC-I into an AP-1–dependent
pathway. (A and B) Western blot analysis of adaptin and
Nef expression in siRNA-treated cells. Astrocytic cells (A) or
CEM T cells (B) were transfected with the indicated siRNA
and transduced with control or Nef-expressing adenoviruses
as described in Materials and methods. Lysates were har-
vested and immunoblotted for the indicated protein. (C and D)
Flow cytometric analysis of siRNA-treated cells. Astrocytic
cells (C) or CEM T cells (D) were stained for surface HLA-A2 ex-
pression (left column) or surface CD4 expression (right column);
shaded curve, control adenovirus; black line, Nef-expressing
adenovirus. (E) Depletion of AP-1 inhibits Nef-dependent
HLA-A2 degradation. CEM T cells were transduced and
treated with siRNAs as described above except that an addi-
tional siRNA transfection was included before transduction.
Lysates were prepared and analyzed by immunoblot to ex-
amine the expression levels of the indicated proteins. 
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AP-1 binds to the Nef–MHC-I complex in 
a dileucine-independent manner
 
Previous studies that have examined the direct interaction of
Nef with AP-1 have found that it depends on the Nef dileucine
motif (Bresnahan et al., 1998; Craig et al., 2000; Janvier et al.,
2003a,b). However, we found that the dileucine motif was not
needed for coprecipitation of AP-1 with MHC-I in CEM T
cells treated with adeno-Nef (Fig. 4 A) or HIV (Fig. S3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200407031/
DC1). These data are consistent with the fact that the dileucine
motif is not necessary for disruption of MHC-I trafficking
(Greenberg et al., 1998a; Mangasarian et al., 1999), and sug-
gests that there is an alternative AP-1 binding site in the Nef–
MHC-I complex.
To rule out the possibility that the interaction we observed
was nonspecific, and to verify that it was dependent on Nef do-
Figure 3. Nef expression results in coprecipi-
tation of AP-1 with HLA-A2. (A) HLA-A2
  pri-
mary human T cells or control CEM-SS cells
that did not express HLA-A2 (Ctrl) were trans-
duced with an HIV molecular clone expressing
Nef (nef
 ), or a matched control HIV that did
not express Nef (nef
 ). Cells were harvested,
and HLA-A2 was immunoprecipitated as de-
scribed in Materials and methods. Proteins that
coprecipitated with HLA-A2 were detected by
Western blotting as indicated. Western blots
of protein inputs are also shown as a control
for relative protein levels in each sample before
immunoprecipitation (Input Controls). Results
are typical of two independent experiments.
(B) AP-3 does not coprecipitate with HLA-A2.
CEM-SS cells (lanes 1 and 4) or CEM HA-HLA-
A2 cells (lanes 2, 3, 5, and 6) were infected
with HIV, and HLA-A2 was recovered by im-
munoprecipitation as described in Materials
and methods. Coprecipitating proteins were
detected by Western blotting (lanes 1–3). A
fraction of the protein input before immunopre-
cipitation was also analyzed to ensure similar protein expression levels (lanes 4–6). Western blots of  -adaptin (AP-3) and  -adaptin (AP-1) were performed
simultaneously using the same antibody concentrations. Apparent molecular masses of protein standards are denoted in kilodaltons on the left.
Figure 4. Analysis of MHC-I and Nef domains that contribute to AP-1 recruitment. (A) Recruitment of AP-1 requires an intact Nef–MHC-I complex and is
independent of the dileucine motif in Nef. CEM-SS cells (lane 1) or CEM HA-HLA-A2 cells (lanes 2–5) were transduced with the indicated adenoviral vector.
The cells were harvested at 72 h and subjected to the coimmunoprecipitation assay. Cells were transduced with each adenovirus to achieve equivalent
Nef expression levels (Input Controls): wild-type NL4-3 Nef (MOI   25); NL4-3 Nef with a NH2-terminal deletion (V10E 17-26, MOI   300); HXB Nef
with a mutation in the dileucine motif (LL164,165AA, MOI   25). (As shown, HXB Nef migrates more slowly on SDS PAGE than NL4-3 Nef. Wild-type HXB
Nef and HXB NefLL164,165AA are directly compared in Fig. S3.) All results are typical of at least two independent experiments. (B) HLA-A2 tyrosine 320
(Y320) is required for efficient Nef binding, AP-1 recruitment, and targeting for degradation. CEM-SS (lanes 1 and 2), CEM HA-HLA-A2 (lanes 3 and 4), or
CEM cells expressing the MHC-I mutant, HA-HLA-A2 Y320A (lanes 5 and 6), were transduced with a control ( ) or Nef-expressing adenovirus ( ). At 72 h
after transduction, HLA-A2 immunoprecipitations were recovered and analyzed by Western blotting as described in Fig. 3. 
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mains important for MHC-I trafficking to lysosomes, we asked
whether AP-1 would coprecipitate with MHC-I in cells express-
ing a Nef mutant (V
 
10
 
E
 
 
 
17-26) that was unable to affect MHC-I
trafficking and to bind MHC-I (Mangasarian et al., 1999; Wil-
liams et al., 2004). As shown in Fig. 4 A, we found that AP-1
did not coprecipitate with HLA-A2 under these conditions.
In addition, we asked whether AP-1 would coprecipitate
with an HLA-A2 mutant lacking a tyrosine residue at position
320 that is necessary for responsiveness to Nef (Greenberg et
al., 1998b; Le Gall et al., 1998). As shown in Fig. 4 B, this mu-
tant was expressed well (Fig. 4 B, input controls, bottom).
However, it was resistant to Nef-dependent MHC-I degrada-
tion, coprecipitated Nef less efficiently, and was defective in
AP-1 recruitment (Fig. 4 B). Thus, these studies indicate that
coprecipitation of AP-1 with HLA-A2 in Nef-expressing cells
was highly specific and depended on amino acid sequences in
Nef and MHC-I that are functionally important for Nef’s ef-
fects on MHC-I cell surface expression.
 
Recruitment of AP-1 requires both the 
cytoplasmic tail of HLA-A2 and the NH
 
2
 
-
terminal 
 
 
 
-helix in Nef
 
The domains of HIV Nef specifically involved in MHC-I traf-
ficking have been well characterized. It is known that disruption
of Nef’s NH
 
2
 
-terminal 
 
 
 
 helix by deletion (V
 
10
 
E
 
 
 
17-26) or
point mutation (M
 
20
 
A), mutation of an acidic cluster (E
 
62-65
 
A),
or mutation of a polyproline repeat (P
 
69/72/75/78
 
A) specifically af-
fects this activity (Greenberg et al., 1998b; Mangasarian et al.,
1999). We have recently reported that each of these mutants
fails to coprecipitate with MHC-I (Williams et al., 2004) and
thus binding to MHC-I may be the primary role of these do-
mains. However, it is also possible that one or more of these do-
mains plays an additional role. To determine whether any of
these domains might also be involved in AP-1 recruitment di-
rectly, we bypassed the requirement for Nef binding by directly
fusing Nef to the COOH terminus of the HLA-A2 cytoplasmic
tail (A2/Nef; Fig. 5 A). As expected, Nef was able to reduce the
cell surface expression of HLA-A2 in cis (Fig. 5 B, left), and to
promote its colocalization with markers of the Golgi apparatus
(Fig. 5 C). In addition, the A2/Nef fusion protein was able to ef-
ficiently coprecipitate AP-1 from T cell lysates in a manner that
was independent of the Nef dileucine motif (Fig. 6 A). However,
the fusion protein was not capable of reducing MHC-I surface
expression in trans (Fig. 5 B, right). Thus, A2/Nef was a useful
reagent to explore which amino acids in Nef and MHC-I were
important for AP-1 recruitment to the Nef–MHC-I complex.
As shown in Fig. 6 A, these studies revealed that muta-
tion of amino acids in the NH
 
2
 
-terminal 
 
 
 
-helix (A2/V
 
10
 
E
 
 
 
17-
26 and A2/M
 
20
 
A) inhibited coprecipitation of AP-1 with the fu-
sion protein. In contrast, disruption of the acidic (A2/E
 
62-65
 
Q)
and polyproline (A2/P
 
72/75
 
A and A2/P
 
75/78
 
A) domains in Nef
had no effect (Fig. 6, A and B). Surprisingly, deletion of the
HLA-A2 cytoplasmic tail (A2
 
 
 
Tail/Nef) or mutation of tyro-
sine 320 in the HLA-A2 cytoplasmic tail (A2Y
 
320
 
A/Nef) also
Figure 5. Characterization of the A2/Nef fusion protein.
(A) Schematic diagram of the A2/Nef fusion protein. (B)
The addition of Nef to the COOH terminus of HLA-A2 re-
sults in a reduction of cell surface expression in cis but not
trans. In the left panel, the effect of Nef in cis was mea-
sured by transducing CEM-SS cells with a bi-cistronic
murine  retrovirus encoding GFP and HLA-A2 (shaded
curve), GFP and A2/Nef (black line), or GFP alone (gray
line). HLA-A2 was detected by staining with mAb BB7.2
and using flow cytometry to gate on the GFP-positive
cells. In the right panel, the effect of A2/Nef in trans was
measured by examining the effect of the fusion protein
(black line) or wild-type HLA-A2 (shaded curve) on stably
expressed HA tagged HLA-A2 (HA-HLA-A2). The negative
control is CEM-SS cells transduced with virus expressing
GFP only (gray line). HA-HLA-A2 was detected by stain-
ing with an mAb directed against HA and using flow
cytometry to gate on the GFP-positive cells. Results are
representative of three independent experiments. (C) The
A2/Nef fusion protein accumulates in the TGN. CEM-SS
cells that stably expressed a tagged late Golgi resident
protein (EYFP-Golgi) were transduced with retroviral con-
structs (A2 or A2/Nef). Cells were stained for HLA-A2
and analyzed by confocal microscopy as described in
Materials and methods. Bar, 5  m. 
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dramatically inhibited coprecipitation of AP-1 by the fusion
protein (Fig. 6 C). Thus, sequences in the Nef NH
 
2
 
-terminal 
 
 
 
helix as well as in the HLA-A2 cytoplasmic tail are necessary
to create a functional AP-1 binding site.
 
Discussion
 
In sum, we have found that in T cells, Nef disrupts MHC-I traf-
ficking after it reaches the TGN to prevent MHC-I cell surface
expression and to promote its degradation in lysosomes. RNAi
treatment of Nef-expressing T cells and astrocytic cells re-
vealed that this activity of Nef required the expression of AP-
1A, but not AP-3. The requirement for AP-1A was further sup-
ported by the fact that we were able to isolate complexes con-
taining MHC-I and AP-1 from Nef-expressing, HIV-infected
primary T cells. The dileucine motif in Nef, which is necessary
for Nef to directly bind AP-1 in other assay systems, was not
needed for AP-1 to bind the Nef–MHC-I complex, suggesting
an alternative means of association. Interestingly, when Nef
was fused to HLA-A2, AP-1 was only recruited when the NH
 
2
 
-
terminal 
 
 
 
 helical domain of Nef was intact and when a full-
length, wild-type HLA-A2 cytoplasmic tail was present. Thus,
amino acids within both Nef and MHC-I were necessary to cre-
ate a binding site for AP-1 in the Nef–MHC-I complex.
The normal function of AP-1 is to sort proteins, such as
lysosomal enzyme receptors at the TGN by linking clathrin to
the cytoplasmic tails of cargo (for review see Dell’Angelica and
Payne, 2001; Robinson and Bonifacino, 2001; Traub, 2003;
Robinson, 2004). For example, the mannose 6-phosphate recep-
tor (MPR), which binds soluble lysosomal enzymes, is sorted at
the TGN by AP-1. It is then transported in vesicles to endo-
somes where the enzymes dissociate and are carried to the lyso-
somes. The MPRs are then recycled back to the TGN to trans-
port more cargo. Thus, Nef-induced AP-1 binding of MHC-I
would be expected to promote TGN accumulation and/or tar-
geting of MHC-I into the endolysosomal pathway (Fig. 7).
Using the yeast two hybrid system (Le Gall et al., 1998;
Piguet et al., 1998; Craig et al., 2000; Erdtmann et al., 2000;
Janvier et al., 2003b), GST-Nef pull-downs (Bresnahan et al.,
1998; Le Gall et al., 1998; Piguet et al., 1998; Janvier et al.,
2003a) or overexpression of a Nef-CD8 chimera in 293 cells
(Bresnahan et al., 1998), a number of investigators have found
that the HIV-1 Nef protein interacts with adaptin subunits and
whole adaptin complexes. A consensus binding domain for
adaptin protein binding (D/EXXXLL) (Bonifacino and Traub,
2003) can be found in Nef and this motif is required for GST-
Nef to pull down AP-1 complexes from mammalian cell ly-
sates (Bresnahan et al., 1998; Janvier et al., 2003a). In addition,
the leucine residues in this motif are required for Nef to down-
modulate CD4, but not MHC-I (Greenberg et al., 1998a; Man-
Figure 6. The cytoplasmic domain of HLA-A2 and the NH2-terminal   helix
of Nef are both required for AP-1 binding. (A and B) The NH2-terminal
 -helix in Nef is necessary for AP-1 recruitment. CEM-SS cells were trans-
duced with the murine retrovirus encoding HLA-A2 or the indicated A2/
Nef fusion constructs. Coprecipitating proteins were detected by Western
blotting of anti-HLA-A2 immunoprecipitations. (C) AP-1 binding to the A2/
Nef fusion protein requires tyrosine 320 (Y320) in the cytoplasmic tail of
HLA-A2. The indicated mutations in the A2/Nef fusion protein were tested
for involvement in AP-1 binding using the assay described above. A2 Tail
is an A2/Nef fusion protein that lacks the entire HLA-A2 cytoplasmic tail.
All results are representative of at least three independent experiments.
White lines indicate that intervening lanes have been spliced out.
Figure 7. Model for MHC-I trafficking in Nef-expressing T cells. To disrupt
MHC-I trafficking, Nef first binds to the MHC-I cytoplasmic tail in the
secretory pathway. The formation of the Nef–MHC-I complex creates a
binding site for AP-1 that is independent of the Nef dileucine motif. This
tertiary complex leads to the recruitment of MHC-I into AP-1–positive
clathrin-coated vesicles destined for degradation in the lysosomes. 
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gasarian et al., 1999). Thus, the dileucine-dependent binding to
adaptins appears to be important for Nef’s effects on CD4.
Our data showing that the dileucine motif is not required
for Nef to promote an interaction between HLA-A2 and AP-1
indicates that there is an alternative binding site for AP-1 in the
Nef–MHC-I complex. It should be noted that there is evidence
for a second AP-1 binding site within Nef that is active in yeast
two hybrid systems (Craig et al., 2000; Erdtmann et al., 2000).
However, existing data suggest that this motif is not able to
support coprecipitation of AP-1 with Nef in mammalian sys-
tems (Bresnahan et al., 1998; Janvier et al., 2003a). These data
can be explained by our results showing that AP-1 recruitment
to HLA-A2 in Nef-expressing cells appeared to result from the
creation of a new binding site for AP-1 that was only active
when Nef was bound to wild-type MHC-I.
The MHC-I cytoplasmic tail itself does not contain a con-
sensus AP-1 binding site (D/EXXXLL or YXX
 
 
 
) (Bonifacino
and Traub, 2003). However, the tyrosine residue at position
320 (Y
 
320
 
) that we show is necessary for Nef to recruit AP-1, is
also required for the normal targeting of MHC-I to endolysoso-
mal compartments in dendritic cells (Lizee et al., 2003). The
mechanism by which MHC-I is normally targeted to these
compartments is unknown, and it is interesting to speculate that
in these cell types Y320 recruits an AP, such as AP-1, that tar-
gets MHC-I to the endolysosomal compartment. Thus, Nef
may be taking advantage of an existing pathway for MHC-I
trafficking that is normally only active in certain cell types.
Previous studies describing the mechanism of Nef’s ef-
fects on MHC-I have focused on the ability of Nef to accelerate
MHC-I endocytosis, rather than on the TGN to lysosomal path-
way we describe (Greenberg et al., 1998b; Le Gall et al., 1998,
2000; Piguet et al., 2000; Blagoveshchenskaya et al., 2002;
Kasper and Collins, 2003). This is most likely due to the fact
that Nef is more active at disrupting transport from the TGN in
T cells than it is in more commonly used cell lines, such as
HeLa cells (Kasper and Collins, 2003). The effect of Nef on
endocytosis has been attributed to the small GTPase ADP-ribo-
sylation factor-6 (Blagoveshchenskaya et al., 2002), which is
normally involved in MHC-I turnover from the cell surface
(Caplan et al., 2002). However, there is new evidence that the
effect of ADP-ribosylation factor-6 may be indirect (Larsen et
al., 2004). In addition, the phosphofurin acidic cluster sorting
protein (PACS-1), which binds Nef via the acidic domain, may
target Nef and/or endocytosed Nef-MHC-I to the TGN in some
cell types (Piguet et al., 2000; Blagoveshchenskaya et al.,
2002). It is known that PACS-1 interacts with AP-1 to promote
TGN recycling (Crump et al., 2001). However, it is unlikely
that the AP-1 interaction we observed here is secondary to
PACS-1 binding, because the PACS-1 binding region (i.e., the
acidic domain) was not needed to recruit AP-1 in our system.
It should also be noted that Nef associates with lipid rafts
and that this localization is important for its effects on MHC-I traf-
ficking (Alexander et al., 2004). It has been proposed that Nef as-
sociation with rafts in the Golgi could trap MHC-I there and per-
haps promote its association with required cellular proteins, such
as AP-1. Further studies are needed to determine whether lipid
rafts are important for Nef–MHC-I–AP-1 complex formation.
In sum, our results indicate that in T cells, the primary ef-
fect of Nef on MHC-I is to promote TGN retention and to ulti-
mately direct MHC-I to lysosomes. We have provided evi-
dence that Nef accomplishes this by acting as an AP, which
stabilizes a physical interaction between AP-1 and MHC-I in
order to target MHC-I into the endolysosomal pathway. These
results have important implications for understanding HIV dis-
ease pathogenesis and for possible pharmaceutical approaches
in combating the development of AIDS.
Materials and methods
Cell culture
CEM T cell lines were maintained in R10 (RPMI supplemented with 10%
FBS, 10 mM Hepes, 2 mM penicillin, streptomycin, and glutamine (P/S/G).
The astrocytic cell lines stably expressing CD4 were maintained in DME
supplemented with 10% FBS and P/S/G. Stable astrocytic and CEM T cell
lines were generated by transduction with MSCV retroviral constructs
pseudotyped with VSV-G as described previously (Kasper and Collins,
2003). Primary T lymphocytes were isolated from buffy coats as described
previously (Collins et al., 1998).
DNA constructs
A nine–amino acid HA epitope tag (YPYDVPDYA) was added to the NH2
terminus of HLA-A2 and HLA-B71 (just after the leader sequence cleavage
site and before the NaeI site; Swann et al., 2001) using the following
primers and HLA-B3501 as the DNA template: forward primer, 5 -GGG-
AATTCCTCAGAATCTCCTCAGACGCCGAG-3 ; reverse primer, 5 -TCC-
CGCCGGCATAGTCGGGTACGTCATACGGATAGGACCCGGCCCAG-
GTCTCGGT-3 . The PCR product was then digested with EcoRI and NaeI
and subcloned into a shuttle vector (New England Biolabs, Inc.). Next, the
following primers were used to amplify the 3  region of HLA-A2 and HLA-
B71: HLA-A2 forward primer, 5 -GAATTCATGGTACCGTGCACG-3 ;
HLA-B71 forward primer, 5 -GGCTCGAGTCAAGCTGTGAGAGACA-
CATC-3 ; HLA-A2 reverse primer, 5 -CCGCTCGAGTCACACTTTACAA-
GCTGT-3 ; HLA-B71 reverse primer, 5 -CTGGGCCGGCTCCCACTCCAT-
GAGGTATTT-3 . The resulting PCR products were digested with NaeI and
XhoI. Finally, the HLA-A2/B71 PCR products and the EcoRI–NaeI frag-
ment purchased from New England Biolabs, Inc. were ligated into MSCV
2.1 (cut with EcoRI and XhoI) in a three-way ligation to generate MSCV
HA-HLA-A2. MSCV HA-HLA-A2 Y320A was cloned by amplifying a portion
of HLA-A2 Y320A (Swann et al., 2001) using the following primers: for-
ward primer, 5 -GCAGCTCAGACCACCAAGCACAAG-3 ; reverse primer
5 -CCGCTCGAGTCACACTTTACAAGCTGT-3 . The PCR product was
then digested with PmlI and XhoI, and was ligated into the same sites in
MSCV HA-HLA-A2 to replace the wild-type sequence.
An adenoviral vector expressing HXB Nef LL164,165AA was gener-
ated by PCR mutagenesis of the HIV molecular clone, HXB-PI (Chen et al.,
1996), using the following primers: mutant forward primer, 5 -AAT-
AAAGGAGAGAACACCAGCGCTGCTCACCCTGTGAGCCTGCATGG-3 ;
with reverse primer (3 hxb-xba), 5 -GCTCTAGATGCTAGAGATTTTCCA-
CACTG-3 , and mutant reverse primer, 5 -TCCATGCAGGCTCACA-
GGGTGAGCAGCGCTGGTGTTCTCTCCTTTATT-3 ; with forward primer
(5  nef) 5 -CGGGATCCATGGGTGGCAAGTGGTCAAA-3 . The resulting
mutant PCR products were mixed and reamplified with 3 hxb-xba and 5 
nef primers, digested with XbaI and XhoI and cloned into the same sites of
HXB-PI. The mutated Nef was then amplified and cloned into an adeno-
viral vector shuttle plasmid as described previously (Swann et al., 2001).
The adenoviral vector expressing Nef V10E 17-26 has been described
previously (Williams et al., 2004).
An HIV molecular clone containing the Nef LL164,165AA mutation
was generated by PCR mutagenesis of the HIV molecular clone, HXB-EP
(Chen et al., 1996), using the following primers: mutant forward primer,
5 -GAAGGAGAGAACACCCGCGCGGCACACCCTGTGAGCCTGCAT-
3 ; with reverse primer (3 hxb-xba), 5 -GCTCTAGATGCTAGAGATTTTC-
CACACTG-3 , and mutant reverse primer, 5 -ATGCAGGCTCACAGGGT-
GTGCCGCGCGGGTGTTCTCTCCTTC-3 ; with forward primer (5  nef) 5 -
GACAGATCCATTCGATTAGTG-3 . The resulting mutant PCR products
were mixed and reamplified with 3 hxb-xba and 5  nef primers, digested
with XbaI and BamHI and cloned into the same sites of HXB-EP.
The A2/Nef fusion constructs were generated as follows: a PCR prod-NEF TARGETS MHC-I INTO AN AP-1 PATHWAY • ROETH ET AL. 911
uct containing the HLA-A2 sequence was generated with the primers; HLA-
A2 5 -CGGGATCCACCATGGTACCGTGCACG-3  and 5 -GGACTAGT-
CACTTTACAAGCTGTGAGAGA-3 . (For HLA-A2 Tail, a different 3  oligo-
nucleotide was used to generate the truncated molecule 5 -GGACTAGTCT-
TCCTCCTCCACATCACAGC-3 ). A PCR product containing wild-type or
mutant Nef sequence (Williams et al., 2004) was generated with the prim-
ers; Nef 5 -GGACTAGTATGGGTGGCAAGTGGTCAAAA-3  and 5 -
GCGAATTCTCAGCAGTTCTTGAAGTACTC-3 . The HLA-A2 PCR product
was digested with BamHI and SpeI, the Nef PCR product was digested with
SpeI and EcoRI. These fragments were then cloned into the BglII and EcoRI
sites of a bi-cistronic retroviral vector expressing an IRES GFP cassette
(pMIG) (Van Parijs et al., 1999) in a three-way ligation. The control HLA-A2
IRES GFP construct was generated using the following primers 5 -CGG-
GATCCACCATGGTACCGTGCACG-3  and 5 -GGTCAACTAGTCACTTTA-
CAAGCTGTGAGAGA-3 . This PCR product was digested with BamHI and
ligated into the BglII and HpaI sites of pMIG. A2 Y320A/Nef was generated
from the A2/Nef template using the following mutant primers: 5  primer; 5 -
AGAAAAGGAGGGAGCGCCTCTCAGGCTGCA-3 , 3  primer; 5 -TGCAG-
CCTGAGAGGCGCTCCCTCCTTTTCT-3 . A2/LL164,165AA was generated
from the A2/Nef template using the following mutant primers: 5  primer; 5 -
ATGCAGGCTCACAGGGTGTGCCGCGCTGGTGTTCTCTCCTTT-3 , 3 
primer; 5 -AAAGGAGAGAACACCAGCGCGGCACACCCTGTGAGCCT-
GCAT-3 .
MSCV-EYFP-Golgi was constructed as follows: EYFP-Golgi (CLON-
TECH Laboratories, Inc.) was digested with NheI and HpaI. This fragment
was ligated into the XbaI and EcoRV sites of pShuttle (Stratagene). The re-
sulting construct was then digested with XhoI and BglII and ligated into the
same sites in MSCV 2.1.
Viral transduction of T cells
CD8-depleted PHA-activated primary T cells or CEM-SS cells were trans-
duced with VSV-G-pseudotyped HIV molecular clones (HXB-EP nef
  and
nef
 ), VSVG-pseudotyped murine retroviruses or adenoviral vectors as de-
scribed previously (Collins et al., 1998; Swann et al., 2001; Kasper and
Collins, 2003). Recombinant replication defective E3-deleted adenovirus
expressing HIV-1 NL4-3 Nef, Nef V10E 17-26, Nef LL164,165AA, or no in-
sert was generated by the University of Michigan Vector Core. For adeno-
viral transductions, CEM cell lines were resuspended in R2 media (RPMI,
2% FBS, P/S/G) at a concentration of 10
6 cells/ml. Adenovirus stocks
were added to a relative multiplicity of infection (MOI; based on 293 cell
infectivity) of 50–200 virus particles/cell. Cells were transferred to 96-well
plates [100  l (10
5 cells) per well]. After 2 h at 37 C, 200  l of R10 me-
dia was added. Cells were harvested at 24–72 h after transduction.
Metabolic labeling and immunoprecipitation
Adeno-transduced CEM T cells were collected and washed twice with D-PBS
(Invitrogen). Cells were incubated in prelabel media [RPMI –Cys –Met (Spe-
cialty Media, Inc.)   10% dialyzed FBS (Invitrogen)] for 15 min at 37 C.
Cells were pulsed with labeling media [prelabel media   150  Ci/ml Pro-
mix-L [
35S] ( 1,000 Ci/mmol; Amersham Biosciences)] for 15 min at 37 C.
Cells were washed twice with R10 and chased in R10 for the indicated pe-
riod of time (5   10
6 cells were used per time point). For some pulse-chase
experiments, bafilomycin A1 (100 nM; Sigma-Aldrich), NH4Cl (25 mM;
Fisher Scientific), or lactacystin (20  M; Sigma-Aldrich) was included in the
chase media. Cells were collected and washed once with D-PBS and lysed
in 1 ml of lysis buffer (50 mM Tris, pH 8, 1% NP-40 (vol/vol), 5 mM MgCl2,
1 mM PMSF) for 30 min on ice, followed by centrifugation to remove insolu-
ble material. Cellular lysates were precleared overnight at 4 C with 1.5
 g of mouse IgG1 (BD Biosciences) and 30  l of protein A/G agarose
(50% slurry; Calbiochem). For immunoprecipitations, 5  g of anti–HLA-A2
(BB7.2) or 3.5  g of anti-transferrin receptor antibody (Oncogene), was
added to the precleared lysate, followed by the addition to 30  l of protein
A/G agarose beads. After 2 h at 4 C, the beads were washed three times
with 1 ml RIPA buffer (Kasper and Collins, 2003). Endo Hf (New England
Biolabs, Inc.) or neuraminidase (New England Biolabs, Inc.) digestion of im-
munoprecipitated material was performed according to the manufacturer’s
protocols. Samples were separated by 10% SDS-PAGE and the gels were
dried and exposed to BioMaxMS films at  80 C. Radio-labeled proteins
were quantitated using a Phosphor storage screen and Typhoon Scanner
followed by processing with Image Quant software.
Immunofluorescence microscopy
CEM cells were allowed to adhere to chambered glass slides coated with
poly-L-lysine (Sigma-Aldrich) for 1 h at 37 C. Cells were then fixed at RT
for 15 min in D-PBS   2% PFA. Next, cell membranes were permeabi-
lized by incubation in D-PBS   0.2% Tween 20 for 15 min at 37 C. Cells
were washed twice with wash buffer (D-PBS, 10 mM Hepes, 10% goat se-
rum [Sigma-Aldrich], 0.025% sodium azide) followed by blocking in
wash buffer (adjusted to 10% goat serum and 10% human serum; Sigma-
Aldrich) for 30 min on ice. For Fig. 1, mouse mAbs were used to detect
LAMP-1 (clone H4A3; BD Biosciences; 1:500) and HLA-A2 (BB7.2, 20
 g/ml). Isotype-specific secondary antibodies were used to distinguish be-
tween these antibodies (anti–mouse IgG1 Alexa-Fluor546 [1:250; Molec-
ular Probes] and anti–mouse IgG2b Alexa-Fluor488 [1:250; Molecular
Probes], respectively). All antibody incubations were performed in wash
buffer on ice for 20 min. Slides were mounted with coverslips using Pro-
long antifade reagent (Molecular Probes). Images were collected using a
confocal microscope (model LSM 510; Carl Zeiss MicroImaging, Inc.) and
processed using Adobe Photoshop 6.0 software. For inhibitor treatment,
adeno-transduced CEM HA-HLA-A2 cells were resuspended in fresh R10
containing 100 nM bafilomycin A1 (Sigma-Aldrich) or solvent alone (DMSO)
and incubated at 37 C for 3 h before adherence.
RNAi treatment
The following duplex siRNAs (Ambion) were used in this study: siGFP,
sense 5 -GCUGACCCUGAAGUUCAUCTT-3 , antisense 5 -GAUGAAC-
UUCAGGGUCAGCTT-3 ; si 3, sense 5 -GGACUACUUUGGUGAGU-
GUTT-3 , antisense 5 -ACACUCACCAAAGUAGUCCTG-3 . The  1A
siRNA was described previously (Hirst et al., 2003). Astrocytoma cells sta-
bly expressing CD4 (373-CD4) were transfected with annealed duplex
siRNAs using Lipofectamine 2000 (Invitrogen) following the manufac-
turer’s protocol. In brief, cells were plated onto 6-well plates (10
5 cells per
well) and the next day each well was transfected using 0.16 nmol siRNA
and 4  l of Lipofectamine 2000 reagent. 24 h later, cells were replated
onto 6-well plates (10
5 cells per well) and the cells were transfected with
siRNA again 24 h after replating. 4–6 h after transfection, the media was
removed and the cells were transduced with adenovirus (MOI   50). Cells
were harvested and analyzed 24 h after transduction.
For experiments using CEM T cells, the cells were first transduced
with adenovirus (MOI   50). 24 h later, 5   10
6 cells were electropo-
rated with 1 nmole siRNA according to the manufacturer’s protocol
(Amaxa Biosystems). The cells were then incubated for 48 h before FACS
and Western blot assays. For Fig. 2 E, the cells were subjected to an ini-
tial siRNA transfection 1 d before the adenoviral transduction, and the ex-
periment was then performed as described above.
Antibodies and Western blot analyses
IP-Western experiments were performed as described previously (Williams
et al., 2004). HA-HLA-A2 was detected using the anti-HA antibody,
HA.11 (1:5,000; Covance). Coprecipitating Nef protein was detected by
Western blotting using antibodies obtained via the NIH AIDS Research
and Reference Reagent Repository, Division of AIDS, NIAID, NIH: poly-
clonal anti-Nef antibody (2949, 1:5,000, a gift from R. Swanstrom, The
University of North Carolina at Chapel Hill, Chapel Hill, NC; Shugars et
al., 1993) or monoclonal anti-Nef (AG11, 1:500 for IP-Westerns and
1:10,000 for crude lysate, a gift from J. Hoxie, University of Pennsylvania,
Philadelphia, PA; Chang et al., 1998). The adaptin subunit,  1, was de-
tected using RY/1 (1:2,500, a gift from L. Traub, University of Pittsburgh,
Pittsburgh, PA; Traub et al., 1995). Other antibodies to AP subunits were
purchased from BD Biosciences:  -adaptin (1:100 for IP-Westerns; 1:1,000
for crude lysate);  -adaptin (1:100 for IP-Westerns; 1:1,000 for crude ly-
sate); and  3 (p47A, 1:500). The HLA-A2–specific mAb, BB7.2 (Parham
and Brodsky, 1981), and anti-Nef antibody, AG11 (Chang et al., 1998),
were purified from ascites fluid as described previously (Kasper and Col-
lins, 2003).
Online supplemental material
Fig. S1 shows that the addition of an HA tag does not affect MHC-I folding,
maturation through the secretory pathway and responsiveness to Nef. Fig.
S2 demonstrates that Nef targets mature MHC-I for degradation in HIV-
infected T cells. Fig. S3 is coimmunoprecipitation and Western blot analy-
sis demonstrating that the dileucine motif is not required for the Nef-MHC-I
to recruit AP-1 in HIV-infected T cells. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200407031/DC1.
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